Product Overview
Common name: Piperazine ferulate tablets
Product name: Baoshengkang
Ingredients: The main ingredient of this product is piperazine ferulate.
Properties: This product is white or off-white film.
Indications: Applicable to various types of glomerular diseases accompanied by microscopic hematuria and hypercoagulable state, such as nephritis, chronic nephritis, early uremia of nephrotic syndrome and coronary heart disease, cerebral infarction, vasculitis and other auxiliary treatment.
Specification: 50mg*50 tablets/box
Usage and dosage: Oral, three times a day, 2-4 tablets each time.
Adverse reactions: No relevant reports have been found.
Contraindication: For those who are allergic to piperazine ferulate.
Note: This product is forbidden to be used in combination with albendazole and pamoate drugs.
Drug interactions: Not clear
Pharmacology and Toxicology: 1. Pharmacology This product has the effects of anticoagulation, anti-platelet aggregation, dilation of microvessels, increased coronary flow and relief of vasospasm.
2. Toxicology The results of acute toxicity experiments showed that the oral LD50 of first-class Kunming mice is 3580.1±251.7mg/kg body weight, and the confidence limit is 95%. The results of long-term toxicity studies indicate that the results of a long-term toxicity experiment by injecting piperazine ferulate 300 mg (30 consecutive times) into healthy adult male dogs every other day proved that piperazine ferulate is less toxic and available for clinical use. Reproductive toxicity studies have shown that there are no obvious embryotoxic effects and teratogenic effects after intraperitoneal injection and intragastric administration of Wistar rats, indicating that the drug is basically safe and reliable in teratogenic. Carcinogenicity research results showed that: through the mutagenic effect of piperazine ferulate on Salmonella typhimurium TA98 and TA100, the micronucleus test of piperazine ferulate and the effect of piperazine ferulate on chromosome aberration of bone marrow cells in mice , Indicating that this product is not carcinogenic.
Pharmacokinetics: The peak time of oral blood absorption of this product is 29 minutes, the distribution phase half-life (t1/2α) is 27 minutes, and the elimination phase half-life (t1/2β) is 5.5 hours. This product is widely distributed in the body. In addition to the liver and kidney blood, it is also distributed in the stomach and small intestine fat. This product is mainly discharged from urine and feces. Can penetrate the placental barrier.
Storage: shading, sealed and stored.
Packaging: Packed in solid medical plastic bottles, 50 pieces/box.
Validity: 24 months
Approval number: National Pharmaceutical Standard H51023368
Company name: Chengdu Hengda Pharmaceutical Co., Ltd.
